Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 324

The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.

The Effects of Medical Management on the Progression of Diabetic Retinopathy in Persons with Type 2 Diabetes

Open access
Chew, Emily Y., Davis, Matthew D., Danis, Ronald P., Lovato, James F., Perdue, Letitia H., Greven, Craig, Genuth, Saul, Goff, David C., Leiter, Lawrence A., Ismail-Beigi, Faramarz, Ambrosius, Walter T.·2014·Ophthalmology

Abstract

Purpose To report additional ocular outcomes of intensive treatment of hyperglycemia, elevated blood pressure, and dyslipidemia in the ACCORD Study. Design Double 2 × 2 factorial multicenter randomized clinical trials in men and women with type 2 diabetes who had established cardiovascular disease and/or cardiovascular risk factors. In the glycemia trial targets of intensive and standard treatment were HbA1c <6.0% and 7.0-7.9%, respectively, and in the blood pressure trial systolic blood pressure of <120 mm Hg and <140 mm Hg, respectively. The dyslipidemia trial compared fenofibrate plus simvastatin vs. placebo plus simvastatin. Participants Of the 5273 ACCORD-Eye participants, 3,472 were enrolled and 2856 had 4-year data (85% of survivors). Methods Eye examinations and fundus photographs were taken at baseline and year 4. Photographs were graded centrally for retinopathy severity and features of macular edema using the Early Treatment Diabetic Retinopathy Study (ETDRS) methods. Primary Outcome Measure 3 or more steps progression on the ETDRS person scale or treatment of retinopathy with photocoagulation or vitrectomy. Results As previously reported, there were significant reductions in the primary outcome in the glycemia and dyslipidemia trials, but no significant effect in the blood pressure trial. Results were similar for retinopathy progression by 1, 2, and 4 or more steps on the person scale and for ≥2 steps on the eye scale. In the subgroup of patients with mild retinopathy at baseline, effect estimates were large (Odds Ratios ∼0.30, P<0.001), but did not reach nominal significance for participants with no retinopathy or for those with moderate to severe retinopathy at baseline. Conclusions Slowing of progression of retinopathy by intensive treatment of glycemia was observed in ACCORD participants, whose average age and diabetes duration were 62 and 10 years, respectively, and who had established cardiovascular disease and/or cardiovascular risk factors. The effect appeared stronger in patients with mild retinopathy. Similar slowing of progression was observed in patients treated with fenofibrate, while no effect was observed with intensive BP treatment. This is the second study to confirm the benefits of fenofibrate in reducing diabetic retinopathy progression and fenofibrate should be considered for treatment of diabetic retinopathy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ophtha.2014.07.019

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 31 references

Cited by

See all 324

Metadata

Authors
Chew, E. Y., Davis, M. D., Danis, R. P., Lovato, J. F., Perdue, L. H., Greven, C., Genuth, S., Goff, D. C., Leiter, L. A., Ismail-Beigi, F., & Ambrosius, W. T.
Venue
Ophthalmology
Publisher
Elsevier BV
Published
2014-12
Volume
121
Issue
12
Pages
2443-2451
ISSN
0161-6420 (ISSN-L)
OpenAlex
W202493534
Cited by
324
References
31
FWCI
19.96
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The Effects of Medical Management on the Progression of Diabetic Retinopathy in Persons with Type 2 Diabetes. https://app.cochat.ai/papers/10.1016/j.ophtha.2014.07.019
The paper
Chew, E. Y., Davis, M. D., Danis, R. P., Lovato, J. F., Perdue, L. H., Greven, C., Genuth, S., Goff, D. C., Leiter, L. A., Ismail-Beigi, F., & Ambrosius, W. T. (2014). The Effects of Medical Management on the Progression of Diabetic Retinopathy in Persons with Type 2 Diabetes. Ophthalmology. https://doi.org/10.1016/j.ophtha.2014.07.019

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.